GEN DC

Genmab A/S

Healthcare


Presented:10/27/2015
Price:DKK667.00
Cap:$6.09B
Current Price:DKK1,600.50
Cap:$15.51B

Presented

Date10/27/2015
PriceDKK667.00
Market Cap$6.09B
Ent Value$4.87B
P/E Ratio82.24x
Book ValueDKK47.17
Div Yield0%
Shares O/S61.07M
Ave Daily Vol327,391
Short IntN/A

Current

PriceDKK1,600.50
Market Cap$15.51B
Genmab A/S is an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer. Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications and daratumumab. The company uses antibody technologies, such as DuoBody, platform for generation of bispecific antibodies and HexaBody, platform which creates effecter function enhanced antibodies. Genmab was founded by Lisa N. Drakeman and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

This idea was presented at the Excellence in Investing Conference, San Francisco on 10/27/2015.
Publicly traded companies mentioned herein: AbbVie Inc (ABBV), Amgen Inc (AMGN), Genmab A/S (GEN DC), Gilead Sciences Inc (GILD), GlaxoSmithKline PLC (GSK), Novartis AG (NVS), Johnson & Johnson (JNJ) 

Highlights

Cancer therapeutics are advancing at a rapid pace, and Vice President Joe Biden’s recent call for a “moon shot” to cure it has only raised awareness of all the research & development (R&D) going on in the space. The presenter thinks that within ten years we will see cures for certain cancers, or that cancer will have been turned into a chronic disease. He is long shares of Genmab (GEN) and explained his preference for undervalued drug development companies with: exceptional R&D, unique and innovative platform(s), diverse pipelines, broad partnerships with big pharma and/ or big biotech, and strong balance sheets (no near term need to turn to equity markets). He also prefers to avoid binary events and single product companies. Taken together, the fact that GEN checks all of these boxes provides for a margin of safety and substantial upside if its pipeline drugs are approved and successfully launched. In particular, Daratumumab (an investigational human IgG1k monoclonal antibody) alone is likely to drive meaningful upside for shareholders, which is why this is his “top pick” right now.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.